FEZF2

Summary

FEZF2 (FEZ family zinc finger 2, HGNC:13506) is a protein-coding gene on chromosome 3p14.2, encoding Fez family zinc finger protein 2 (Q8TBJ5). Transcription repressor.

Predicted to enable several functions, including DNA-binding transcription factor activity, RNA polymerase II-specific; RNA polymerase II cis-regulatory region sequence-specific DNA binding activity; and zinc ion binding activity. Predicted to be involved in regulation of gene expression. Predicted to act upstream of or within several processes, including negative regulation of transcription by RNA polymerase II; nervous system development; and regulation of neuron differentiation. Predicted to be active in nucleus.

Source: NCBI Gene 55079 — RefSeq curated summary.

At a glance

• Gene–disease (curated): neurodevelopmental disorder (Strong, GenCC) — +1 more curated relationship
• GWAS associations: 2
• Clinical variants (ClinVar): 77 total — 2 pathogenic, 3 likely-pathogenic
• MANE Select transcript: NM_018008

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13506
Approved symbol	FEZF2
Name	FEZ family zinc finger 2
Location	3p14.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ10142, FKSG36, TOF, FEZL, Zfp312
Ensembl gene	ENSG00000153266
Ensembl biotype	protein_coding
OMIM	607414
Entrez	55079

Gene structure

Transcript identifiers

Ensembl transcripts: 4 — 4 protein_coding

ENST00000283268, ENST00000475839, ENST00000486811, ENST00000951993

RefSeq mRNA: 1 — MANE Select: NM_018008 NM_018008

CCDS: CCDS2897

Canonical transcript exons

ENST00000283268 — 5 exons

Exon	Start	End
ENSE00001009883	62371533	62371667
ENSE00001009885	62372017	62372926
ENSE00001206205	62373279	62373550
ENSE00001949701	62369681	62370342
ENSE00002376776	62371217	62371349

Expression profiles

Bgee: expression breadth broad, 90 present calls, max score 98.86.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.7843 / max 195.1946, expressed in 174 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
42803	0.2683	113
42798	0.2178	82
42800	0.1941	78
42805	0.1897	50
42806	0.1673	54
42802	0.1600	89
42799	0.1594	79
42808	0.1582	66
42801	0.1222	70
42807	0.1140	52

Top tissues by expression

269 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
cortical plate	UBERON:0005343	98.86	gold quality
ventricular zone	UBERON:0003053	94.37	gold quality
ganglionic eminence	UBERON:0004023	90.69	gold quality
sural nerve	UBERON:0015488	90.13	gold quality
CA1 field of hippocampus	UBERON:0003881	86.71	gold quality
Ammon’s horn	UBERON:0001954	85.69	gold quality
endothelial cell	CL:0000115	85.43	gold quality
anterior cingulate cortex	UBERON:0009835	84.48	gold quality
cingulate cortex	UBERON:0003027	84.34	gold quality
amygdala	UBERON:0001876	81.13	gold quality
cerebral cortex	UBERON:0000956	81.06	gold quality
secondary oocyte	CL:0000655	80.84	gold quality
neocortex	UBERON:0001950	80.45	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	80.27	gold quality
prefrontal cortex	UBERON:0000451	80.10	gold quality
postcentral gyrus	UBERON:0002581	79.67	gold quality
temporal lobe	UBERON:0001871	79.30	gold quality
Brodmann (1909) area 9	UBERON:0013540	79.19	gold quality
frontal cortex	UBERON:0001870	79.14	gold quality
entorhinal cortex	UBERON:0002728	78.69	gold quality
right frontal lobe	UBERON:0002810	78.64	gold quality
parietal lobe	UBERON:0001872	78.27	gold quality
superior frontal gyrus	UBERON:0002661	77.73	gold quality
telencephalon	UBERON:0001893	76.87	gold quality
oocyte	CL:0000023	76.19	gold quality
embryo	UBERON:0000922	74.55	gold quality
primary visual cortex	UBERON:0002436	72.23	gold quality
forebrain	UBERON:0001890	72.17	gold quality
Brodmann (1909) area 46	UBERON:0006483	71.50	silver quality
occipital lobe	UBERON:0002021	70.89	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-HCAD-5	yes	384.80
E-ANND-3	no	2.14

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

9 targets.

Target	Regulation
CCN2
CS
FEZF2
HES5	Repression
IAPP
MDM2	Repression
SEMA5A	Activation
SPON1
TBR1

JASPAR motifs

Motif	Name	Family
MA2341.1	FEZF2	More than 3 adjacent zinc fingers

JASPAR matrix evidence (PMIDs): PMID:19879846

Upstream regulators (CollecTRI, top): FEZF2, NEUROG2, PAX6, RNF2, TBR1

miRNA regulators (miRDB)

64 targeting FEZF2, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-3924	100.00	72.09	2394
HSA-LET-7A-3P	100.00	74.03	3932
HSA-LET-7B-3P	100.00	74.08	3913
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-520D-5P	99.98	73.34	4883
HSA-MIR-524-5P	99.98	73.43	4882
HSA-MIR-590-3P	99.96	74.34	6478
HSA-MIR-493-5P	99.96	72.47	2382
HSA-LET-7C-3P	99.95	73.42	2862
HSA-MIR-5680	99.91	69.83	3421
HSA-MIR-4731-5P	99.89	67.23	2537
HSA-LET-7A-2-3P	99.87	70.53	1921
HSA-LET-7G-3P	99.85	70.43	1929
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-3121-3P	99.82	71.96	3630
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-92A-2-5P	99.75	67.01	2164
HSA-MIR-149-3P	99.72	68.22	3963
HSA-MIR-6883-5P	99.69	68.05	3785
HSA-MIR-1290	99.59	69.90	2079
HSA-MIR-4687-3P	99.48	66.41	968
HSA-MIR-4728-3P	99.47	68.94	981
HSA-MIR-4666A-5P	99.41	69.72	1887
HSA-MIR-3140-5P	99.39	69.04	1136

Literature-anchored findings (GeneRIF, showing 8)

• ZNF312 and other brain-layer biomarkers have area dependent expressions in the human fetal cortex. (PMID:20570630)
• the feasibility of employing genomic SELEX to identify vertebrate transcription factor binding sites and target genes and reveal Fezf2 as a transcription activator and a candidate for evaluation in human microcephaly. (PMID:21471212)
• overexpression of EZH2 was frequently detected in NPC tumors. Thus, we have identified FEZF2 as a novel 3p14.2 TSG frequently inactivated by promoter methylation in NPC, which functions as a repressor downregulating multiple oncogene expression (PMID:23677067)
• This study reports the differentiation of a hFezf2-YFP human embryonic stem cell reporter line into corticofugal projection neurons. (PMID:23826257)
• Fezf1 and Fezf2 accomplish both independent and redundant functions across diverse tissue and cell types. [Review] (PMID:24913420)
• FEZF2 expression has a role in cell proliferation and differentiation in adult neural stem cells. (PMID:25319688)
• Fezf2 expression is downregulated in bladder cancer tissues and cell lines compared to adjacent non-tumor tissues and normal urothelial cells. Overexpression of Fezf2 significantly inhibited the proliferation, growth, migration, and invasion of bladder cancer cells, and attenuated angiogenesis, while knockdown of Fezf2 had the opposite effect. (PMID:29925938)
• Rare predicted deleterious FEZF2 variants are associated with a neurodevelopmental phenotype. (PMID:38425142)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
danio_rerio	fezf2	ENSDARG00000070677
mus_musculus	Fezf2	ENSMUSG00000021743
rattus_norvegicus	Fezf2	ENSRNOG00000009206

Paralogs (28): ZNF280C (ENSG00000056277), ZBTB25 (ENSG00000089775), PRDM13 (ENSG00000112238), BCL6 (ENSG00000113916), FEZF1 (ENSG00000128610), ZBTB46 (ENSG00000130584), PRDM12 (ENSG00000130711), ZNF280D (ENSG00000137871), NACC2 (ENSG00000148411), ZBTB7B (ENSG00000160685), NACC1 (ENSG00000160877), BCL6B (ENSG00000161940), GFI1 (ENSG00000162676), GFI1B (ENSG00000165702), ZBTB49 (ENSG00000168826), ZNF280A (ENSG00000169548), ZNF581 (ENSG00000171425), ZNF524 (ENSG00000171443), ZBTB26 (ENSG00000171448), ZBTB21 (ENSG00000173276), ZNF683 (ENSG00000176083), ZBTB33 (ENSG00000177485), ZBTB3 (ENSG00000185670), ZBTB6 (ENSG00000186130), ZBTB14 (ENSG00000198081), ZBTB12 (ENSG00000204366), ZNF580 (ENSG00000213015), ZNF280B (ENSG00000275004)

Protein

Protein identifiers

Fez family zinc finger protein 2 — Q8TBJ5 (reviewed: Q8TBJ5)

Alternative names: Forebrain embryonic zinc finger-like protein 2, Zinc finger protein 312, Zinc finger protein Fez-like

All UniProt accessions (2): Q8TBJ5, A0A140VKG3

UniProt curated annotations — full annotation on UniProt →

Function. Transcription repressor. Required for the specification of corticospinal motor neurons and other subcerebral projection neurons. May play a role in layer and neuronal subtype-specific patterning of subcortical projections and axonal fasciculation. Controls the development of dendritic arborization and spines of large layer V pyramidal neurons. May be involved in innate immunity.

Subcellular location. Nucleus.

Similarity. Belongs to the krueppel C2H2-type zinc-finger protein family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TBJ5-1	1	yes
Q8TBJ5-2	2

RefSeq proteins (1): NP_060478* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily

Pfam: PF00096, PF13912

UniProt features (15 total): zinc finger region 6, sequence variant 3, splice variant 2, chain 1, sequence conflict 1, region of interest 1, short sequence motif 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TBJ5-F1	55.45	0.00

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 225 (showing top): GOBP_FOREBRAIN_NEURON_DEVELOPMENT, GOBP_DENDRITE_DEVELOPMENT, GOBP_DENTATE_GYRUS_DEVELOPMENT, RRAGTTGT_UNKNOWN, LEE_NEURAL_CREST_STEM_CELL_DN, GOBP_NEURON_RECOGNITION, GOBP_NEGATIVE_REGULATION_OF_NEURON_DIFFERENTIATION, BENPORATH_ES_WITH_H3K27ME3, HNF3ALPHA_Q6, GOBP_BEHAVIOR, PAX4_01, GOBP_POSITIVE_REGULATION_OF_NEURON_DIFFERENTIATION, CGGAARNGGCNG_UNKNOWN, AACYNNNNTTCCS_UNKNOWN, GOBP_NEUROGENESIS

GO Biological Process (26): axonal fasciculation (GO:0007413), locomotory behavior (GO:0007626), negative regulation of cell population proliferation (GO:0008285), regulation of gene expression (GO:0010468), dendrite development (GO:0016358), dentate gyrus development (GO:0021542), forebrain anterior/posterior pattern specification (GO:0021797), cerebral cortex GABAergic interneuron migration (GO:0021853), commitment of neuronal cell to specific neuron type in forebrain (GO:0021902), cell dedifferentiation (GO:0043697), negative regulation of neuron differentiation (GO:0045665), positive regulation of neuron differentiation (GO:0045666), neuron fate determination (GO:0048664), regulation of neurogenesis (GO:0050767), regulation of axon guidance (GO:1902667), negative regulation of transcription by RNA polymerase II (GO:0000122), nervous system development (GO:0007399), telencephalon development (GO:0021537), cerebral cortex neuron differentiation (GO:0021895), central nervous system neuron differentiation (GO:0021953), cell differentiation (GO:0030154), neuron differentiation (GO:0030182), forebrain development (GO:0030900), positive regulation of DNA-templated transcription (GO:0045893), positive regulation of transcription by RNA polymerase II (GO:0045944), GABAergic neuron differentiation (GO:0097154)

GO Molecular Function (9): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription repressor activity, RNA polymerase II-specific (GO:0001227), DNA-binding transcription activator activity, RNA polymerase II-specific (GO:0001228), chromatin binding (GO:0003682), zinc ion binding (GO:0008270), transcription cis-regulatory region binding (GO:0000976), DNA binding (GO:0003677), sequence-specific DNA binding (GO:0043565), metal ion binding (GO:0046872)

GO Cellular Component (1): nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
anatomical structure development	3
neuron differentiation	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	3
regulation of neuron differentiation	2
DNA-binding transcription factor activity, RNA polymerase II-specific	2
neuron recognition	1
axon development	1
neuron projection fasciculation	1
behavior	1
cell population proliferation	1
regulation of cell population proliferation	1
negative regulation of cellular process	1
gene expression	1
regulation of macromolecule biosynthetic process	1
neuron projection development	1
hippocampus development	1
anterior/posterior pattern specification	1
forebrain regionalization	1
interneuron migration from the subpallium to the cortex	1
cerebral cortex GABAergic interneuron development	1
interneuron migration	1
forebrain neuron fate commitment	1
dedifferentiation	1
cellular developmental process	1
negative regulation of cell differentiation	1
positive regulation of cell differentiation	1
cell fate determination	1
neuron fate commitment	1
neurogenesis	1
regulation of nervous system development	1
regulation of cell development	1
axon guidance	1
regulation of neuron projection development	1
regulation of chemotaxis	1
regulation of transcription by RNA polymerase II	1
transcription by RNA polymerase II	1
negative regulation of DNA-templated transcription	1
system development	1
forebrain development	1
forebrain neuron differentiation	1

Protein interactions and networks

STRING

1410 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
FEZF2	TBR1	Q16650	932
FEZF2	SOX5	P35711	758
FEZF2	SATB2	Q9UPW6	747
FEZF2	NEUROD6	Q96NK8	713
FEZF2	FOXG1	P55315	699
FEZF2	PAX6	P26367	695
FEZF2	CUX2	O14529	675
FEZF2	AIRE	O43918	613
FEZF2	EMX1	Q04741	601
FEZF2	TH	P07101	567
FEZF2	CUX1	P39880	564
FEZF2	NEUROG2	Q9H2A3	560
FEZF2	RORB	Q92753	557
FEZF2	LHX2	P50458	554
FEZF2	EMX2	Q04743	544

IntAct

3 interactions, top by confidence:

A	B	Type	Score
APP	FEZF2	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (6): FEZF2 (Affinity Capture-MS), FEZF2 (Affinity Capture-MS), FEZF2 (Two-hybrid), FEZF2 (Cross-Linking-MS (XL-MS)), HDAC1 (Affinity Capture-Western), FEZF2 (Affinity Capture-Western)

ESM2 similar proteins: A0JPB4, A0PJY2, B0K011, O08876, O15090, O57415, O62651, O70237, O75626, O95863, P19544, P22561, P41183, P49952, P55878, P86413, Q02085, Q08DS3, Q0IHB8, Q0P4W9, Q0VDQ9, Q25C93, Q28G88, Q2TAR3, Q2VWH6, Q32NK7, Q3MHQ4, Q3T135, Q3UH06, Q567J8, Q5T0B9, Q5VTD9, Q5XJQ7, Q60636, Q62255, Q66JF8, Q6AY34, Q6DBW0, Q6NRM0, Q804Q5

Diamond homologs: A0PJY2, Q0P4W9, Q0VDQ9, Q25C93, Q28G88, Q2TAR3, Q2VWH6, Q804Q5, Q8TBJ5, Q9ESP5, Q9IAJ2, Q9VQ56, P60319

SIGNOR signaling

2 interactions.

A	Effect	B	Mechanism
TBR1	“down-regulates quantity by repression”	FEZF2	“transcriptional regulation”
FEZF2	“down-regulates quantity by repression”	MDM2	“transcriptional regulation”

Disease & clinical

Clinical variants and AI predictions

ClinVar

77 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	2
Likely pathogenic	3
Uncertain significance	67
Likely benign	2
Benign	2

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
3774179	NM_018008.4(FEZF2):c.1014C>A (p.Cys338Ter)	Pathogenic
4715858	NM_018008.4(FEZF2):c.930C>A (p.Cys310Ter)	Pathogenic
3367203	NM_018008.4(FEZF2):c.801_802dup (p.Gly268fs)	Likely pathogenic
3377075	NM_018008.4(FEZF2):c.1266C>G (p.Cys422Trp)	Likely pathogenic
4280601	NM_018008.4(FEZF2):c.1298_1302del (p.Lys433fs)	Likely pathogenic

SpliceAI

582 predictions. Top by Δscore:

Variant	Effect	Δscore
3:62371211:CGTTA:C	donor_loss	1.0000
3:62371212:GTTAC:G	donor_loss	1.0000
3:62371213:TTACC:T	donor_loss	1.0000
3:62371214:TAC:T	donor_loss	1.0000
3:62371216:C:CG	donor_loss	1.0000
3:62371345:TTTTC:T	acceptor_gain	1.0000
3:62371346:TTTC:T	acceptor_gain	1.0000
3:62371347:TTC:T	acceptor_gain	1.0000
3:62371348:TC:T	acceptor_gain	1.0000
3:62371349:CC:C	acceptor_gain	1.0000
3:62371350:C:CC	acceptor_gain	1.0000
3:62371351:T:G	acceptor_loss	1.0000
3:62371629:CGGCA:C	acceptor_gain	1.0000
3:62371630:G:T	acceptor_gain	1.0000
3:62371633:A:C	acceptor_gain	1.0000
3:62371665:CAC:C	acceptor_gain	1.0000
3:62371669:T:A	acceptor_loss	1.0000
3:62372016:C:A	donor_loss	1.0000
3:62370339:TTCC:T	acceptor_gain	0.9900
3:62370340:TCC:T	acceptor_gain	0.9900
3:62370341:CC:C	acceptor_gain	0.9900
3:62370341:CCC:C	acceptor_gain	0.9900
3:62370342:CC:C	acceptor_gain	0.9900
3:62370343:C:CC	acceptor_gain	0.9900
3:62370343:CTACA:C	acceptor_loss	0.9900
3:62371346:TTTCC:T	acceptor_gain	0.9900
3:62371347:TTCCT:T	acceptor_gain	0.9900
3:62371348:TCCT:T	acceptor_gain	0.9900
3:62371528:CGTA:C	donor_loss	0.9900
3:62371529:GTAC:G	donor_loss	0.9900

AlphaMissense

0 scored. Top likely-pathogenic:

dbSNP variants (sampled 300 via entrez): RS1001044554 (3:62371211 C>G,T), RS1003033668 (3:62371733 G>A,T), RS1003370551 (3:62375236 G>A,T), RS1003382970 (3:62373497 G>A), RS1003501078 (3:62373176 C>A,T), RS1004779492 (3:62370556 C>T), RS1005437757 (3:62373542 C>T), RS1005906283 (3:62373852 G>C), RS1006614711 (3:62374002 C>A,T), RS1006842890 (3:62372119 C>A,G), RS1007089745 (3:62374270 G>A), RS1007838788 (3:62370544 C>A,G,T), RS1008282426 (3:62374550 G>A,C), RS1008488753 (3:62369555 C>T), RS1009022093 (3:62375438 T>C)

Disease associations

OMIM: gene MIM:607414 | disease phenotypes: MIM:610532

GenCC curated gene-disease

Disease	Classification	Inheritance
neurodevelopmental disorder	Strong	Autosomal dominant
complex neurodevelopmental disorder	Limited	Autosomal dominant

Mondo (3): neurodevelopmental disorder (MONDO:0700092), hypomyelinating leukodystrophy 5 (MONDO:0012514), complex neurodevelopmental disorder (MONDO:0100038)

Orphanet (1): Hypomyelination-congenital cataract syndrome (Orphanet:85163)

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

2 associations (top):

Study	Trait	p-value
GCST009391_1585	Metabolite levels	7.000000e-06
GCST90000047_46	Age at first sexual intercourse	5.000000e-08

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0010349	cholesteryl ester 20:5 measurement
EFO:0009749	age at first sexual intercourse measurement

MeSH disease descriptors (2)

Descriptor	Name	Tree numbers
D065886	Neurodevelopmental Disorders	F03.625
C567166	Leukodystrophy, Hypomyelinating, 5 (supp.)

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects cotreatment, decreases expression, affects expression	7
trichostatin A	affects cotreatment, decreases expression	3
mercuric bromide	decreases expression, affects cotreatment	2
entinostat	decreases expression, affects cotreatment	2
Vorinostat	affects cotreatment, decreases expression	2
Panobinostat	affects cotreatment, decreases expression	2
Phenylmercuric Acetate	affects cotreatment, decreases expression	2
p-Chloromercuribenzoic Acid	affects cotreatment, decreases expression	2
methylmercuric chloride	decreases expression	1
bisphenol A	affects cotreatment, decreases methylation	1
ethyl-p-hydroxybenzoate	increases expression	1
arsenite	increases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, decreases expression	1
dorsomorphin	affects cotreatment, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Fulvestrant	affects cotreatment, decreases methylation	1
Air Pollutants	affects methylation, increases abundance	1
Arsenic	increases methylation	1
Benzo(a)pyrene	affects methylation, increases methylation	1
Diethylhexyl Phthalate	decreases expression	1
Nitrogen Dioxide	increases abundance, affects methylation	1
Plant Extracts	affects cotreatment, decreases expression	1
Silver	decreases expression	1
Tretinoin	decreases expression	1
Aflatoxin B1	decreases methylation	1
Particulate Matter	affects methylation, increases abundance	1

Clinical trials (associated diseases)

204 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT04586348	PHASE4	UNKNOWN	Prenatal Iodine Supplementation and Early Childhood Neurodevelopment
NCT04873115	PHASE4	UNKNOWN	Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties,
NCT02559102	PHASE3	COMPLETED	Dexmedetomidine Sedation Versus General Anaesthesia for Inguinal Hernia Surgery in Infants
NCT02757079	PHASE3	COMPLETED	Study of the Efficacy and Safety of NPC-15 for Sleep Disorders of Children With Neurodevelopmental Disorders
NCT06915480	PHASE3	RECRUITING	Reducing Missed Appointments
NCT07377032	PHASE3	RECRUITING	TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders
NCT02909959	PHASE2	COMPLETED	Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
NCT06081348	PHASE2	RECRUITING	Sertraline vs. Placebo in the Treatment of Anxiety in Children and AdoLescents With NeurodevelopMental Disorders
NCT06352372	PHASE2	COMPLETED	Safety and Efficacy of tPBM for Epileptiform Activity in Autism
NCT00503191	PHASE1	COMPLETED	NeuroModulation Technique Treatment of Autism
NCT04475848	PHASE1	COMPLETED	A Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of RO6953958 in Healthy Participants
NCT06300398	PHASE1	COMPLETED	IAMA-6 Oral Dose Study in Healthy Adults
NCT06310681	Not specified	COMPLETED	Pilot Testing of a Co-adapted Group Programme for Parents/Carers of Children With Complex Neurodisability
NCT07303049	Not specified	NOT_YET_RECRUITING	Cognitive Benefit of Intensive Rehabilitation Using Rhythmic Music Training in Children With Complex Neurodevelopmental Disorder
NCT01783041	PHASE2/PHASE3	COMPLETED	Effect of Early L-Carnitine Supplementation on Neurodevelopmental Outcomes in Very Preterm Infants
NCT05767385	PHASE2/PHASE3	RECRUITING	Fetal Cerebrovascular Autoregulation in Congenital Heart Disease and Association With Neonatal Neurobehavior
NCT05675098	EARLY_PHASE1	NOT_YET_RECRUITING	Central Nervous System Stimulants and Physical Function in Children With Cerebral Palsy
NCT00783783	Not specified	COMPLETED	CYP2D6 Pharmacogenetics in Risperidone-Treated Children
NCT01778504	Not specified	RECRUITING	Studying Childhood-onset Behavioral, Psychiatric, and Developmental Disorders
NCT01850784	Not specified	UNKNOWN	High Energy Formula Feeding in Infants With Congenital Heart Disease
NCT01922791	Not specified	COMPLETED	Nutrition and Pregnancy Intervention Study
NCT01942525	Not specified	UNKNOWN	Influence of Intrauterine Growth Restriction on Amplitude-integrated EEG in Preterm Infants
NCT02003170	Not specified	COMPLETED	Etiology and Early Diagnosis of Neurodevelopmental Disorders
NCT02118649	Not specified	ACTIVE_NOT_RECRUITING	Enhancing Behavior and Brain Response to Visual Targets Using a Computer Game
NCT02557191	Not specified	TERMINATED	Biomarkers, Neurodevelopment and Preterm Infants
NCT02690675	Not specified	COMPLETED	Iron Supplement Effect on Child Development
NCT02694003	Not specified	COMPLETED	Better Nights, Better Days for Children With Neurodevelopment Disorders
NCT02792894	Not specified	COMPLETED	Family Networks (FaNs) for Children With Developmental Disorders and Delays
NCT02871674	Not specified	UNKNOWN	Good Night Project: Behavioural Sleep Interventions for Children With ADHD: A Randomised Controlled Trial
NCT02887157	Not specified	COMPLETED	Analyzing Retinal Microanatomy in ROP
NCT02898298	Not specified	COMPLETED	Positive Emotion Regulation Training in Children, Adolescents and Young Adults With and Without Developmental Disorder
NCT02912780	Not specified	UNKNOWN	Introduction of Microsystems in a Level 3 Neonatal Intensive Care Unit
NCT03023293	Not specified	COMPLETED	n-3 PUFAs, Irisin and Maternal Glucose Metabolism From Pregnancy to Postpartum
NCT03023644	Not specified	COMPLETED	Improving Neurodevelopmental Outcomes in Children With Congenital Heart Disease: An Intervention Study
NCT03032991	Not specified	UNKNOWN	Early Biomarkers of Neurodevelopment in Offspring of Diabetic Mothers
NCT03088189	Not specified	TERMINATED	Effect of Parental Peri-conceptional Vitamin B12 Supplementation on Infant Neurocognitive Development in Offspring
NCT03096028	Not specified	COMPLETED	Developmental Origins of Mental Health Disorders
NCT03148782	Not specified	COMPLETED	Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase
NCT03172104	Not specified	COMPLETED	Neurobehavioural Development of Infants Born <30 Weeks Gestational Age Between Birth and Five Years of Age
NCT03222375	Not specified	RECRUITING	SQUED™ Series 28.1 Home-use and Treatment of Autowave Reverberator of Autism